



Special Lecture

Rethinking Risks: Certain pre-formed donor-specific HLA Antibodies are not pathogenic in kidney transplantation

Rajalingam Raja

Immunogenetics and Transplantation Laboratory,

University of California San Francisco

USA

Abstract

In this presentation, I will discuss the outcome analysis of 1673 (32.3% had a CPRA of $\geq 80\%$) consecutive deceased donor kidney transplants at UCSF. My presentation have the following learning objectives:

1. Understand the strategies for assessing clinically irrelevant preformed donor-specific HLA antibodies (pfDSA) to enhance the likelihood of highly sensitized candidates receiving compatible deceased donor kidney transplants.
2. Learn the outcomes of pfDSA-positive transplants (20.5% of the cohort) are comparable to pfDSA-negative transplants in the cohort of 1673 consecutive deceased donor kidney transplants, among which over one third had a CPRA of 80% or higher.
3. Comprehend the long-term outcomes of kidney transplants among highly sensitized candidates, involving strong pfDP-DSA, even in cases of a positive flow crossmatch, without undergoing desensitization.